Dermal Laboratories Ltd.

Rise in cellular assay demand for drug discovery screening procedures is driving the in-vitro toxicology testing market North America is witnessing substantial market growth due to rise in focus on drug discovery in the U.S. and Canada WILMINGTOM, Del., Dec. 6, 2022 /PRNewswire/ -- According to a market report published by Transparency Market Research, the global in-vitro toxicology testing market was valued at US$ 27 Bn in 2021. The past few years have witnessed increasing number of new diseases, which has put the focus on developing new drugs to help cure patients suffering from these diseases. The demand for toxicology testing methods such as in-vitro toxicology testing has risen in a bid to ensure the end product is free of any toxic content. Application areas that use in-vitro toxicology testing market include systemic toxicology, cardiotoxicity, ocular toxicity, and dermal toxicity. Leading players in the in-vitro toxicology testing market are collaborating with smaller players in order to expand presence in the global market and increase revenue. Get Exclusive PDF Sample Copy of In-vitro Toxicology Testing Market – Key Findings of In-vitro Toxicology Testing Market Study Rise in Cellular Assay Demand in Drug Discovery Screening Procedures Boosting Market Growth: Based on method, the global in-vitro toxicology testing market can be classified into cellular assay, biochemical assay, ex-vivo, and in-silico. Cellular assay emerged as the dominant segment in 2021. This is ascribed to increasing cellular assay deployment in drug discovery screening procedures to identify cytotoxicity. Furthermore, cellular assays have been used in the initial stages of drug development by leading players in the pharmaceutical industry, which has triggered the growth of the cellular assay segment. In-vitro Toxicology Testing Market - Key Drivers Increase in the number of pharma companies focusing on R&D activities due to surge in competition in the healthcare industry is one of the key factors driving the global in-vitro toxicology testing market Improvements to existing in-vitro toxicology tests to examine medicines' influence on cells and tissues are expected to fuel market expansion during the forecast period Rise in demand for ex-vivo toxicology testing as it permits drug screening tests to be conducted in sterile and dynamic environment is likely to augment the in-vitro toxicology testing market between 2022 and 2032 Government initiatives and measures such as offering finances to leading players for research activities and providing favorable reimbursement policies is expected to help industry growth during the forecast timeline Ask for References – In-vitro Toxicology Testing Market - Regional Market Insights North America is a highly attractive region for in-vitro toxicology testing owing to factors such as increase in focus on drug discovery by governments and introduction of biosimilar drugs in countries such as the U.S. Furthermore, stringent standards for medicine development in the U.S. have led to increase in deployment of in-vitro toxicology testing and helped in business growth. In-vitro Toxicology Testing Market - Key Players The global in-vitro toxicology testing market is competitive due to the presence of several prominent players. Entry of new players during the forecast period is likely to intensify competition in the market. Leading players strive to establish research centers in countries offering key resources such as land and labor at affordable prices for in-vitro toxicology testing procedures. For instance, in September 2019, Covance announced the launch of new research and development center in China in a bid to bolster its in-vitro toxicology testing business in Asia Pacific. Well-established players in the global market include GE Healthcare, Abbott, Thermo Fischer Scientific, Agilent Technologies, and Merck KGaA. The global market is segmented as follows: By Method Cellular Assay Live Cells Fixed Cells Biochemical Assay In-Silico Ex-vivo By End-use Pharmaceutical Industry Cosmetics & Household Products Academic Institutes and Research Laboratories Diagnostics Chemical Industry Food Industry By Technology Cell Culture Technology High Throughput Technology Molecular Imaging OMICS Technology By Application Systemic Toxicology Dermal Toxicity Endocrine Disruption Ocular Toxicity Others By Region North America Latin America Europe Asia Pacific Middle East & Africa Make an Enquiry Before Buying – Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Latest Healthcare Research Reports by Transparency Market Research: Hysteroscopy Procedures Market: Hysteroscopy procedures market is anticipated to reach more than US$ 9 Bn by the end of 2032 and to grow at a CAGR of 8.4% from 2022 to 2032. Medical Device Analytical Testing Outsourcing Market: Medical Device Analytical Testing Outsourcing Market is anticipated to reach more than US$ 16.7 Bn by the end of 2032 and to grow at a CAGR of 11.2% from 2022 to 2031. Cold Plasma Market: Cold plasma market is anticipated to reach more than US$ 17.3 Bn by the end of 2032 and to grow at a CAGR of 18.6% from 2022 to 2032. Mesenchymal Stem Cells Market: Mesenchymal Stem Cells Market is anticipated to reach more than US$ 16.4 Bn by the end of 2031 and to grow at a CAGR of 17.3% from 2022 to 2031. Operating Room Integration Market: Operating Room Integration Market is anticipated to reach more than US$ 7.2 Bn by the end of 2031 and to grow at a CAGR of 13.9% from 2022 to 2032. Near Infrared Imaging Market: Near Infrared Imaging Market is anticipated to reach more than US$ 785.1 Mn by the end of 2032 and to grow at a CAGR of 12.7% from 2022 to 2032. Viral Vector Production Market: Viral vector creation market is worth more than US$ 1.3 Bn by 2032 and it is estimated to expand at a CAGR of 28.3% from 2022 to 2032. About Transparency Market Research Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - Contact Nikhil Sawlani Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Website: Blog: Email: [email protected] Logo: SOURCE Transparency Market Research

DUBLIN, June 17, 2022 /PRNewswire/ -- The "Generic Pharmaceuticals Global Market Report 2022: By Therapy, By Distribution, By Type, By Drug" report has been added to ResearchAndMarkets.com's offering. The global generic pharmaceuticals market is expected to grow from $302.39 billion in 2021 to $332.43 billion in 2022 at a compound annual growth rate (CAGR) of 9.9%. The market is expected to reach $426.30 billion in 2026 at a CAGR of 6.4%. The generic pharmaceuticals market consists of sales of generic pharmaceuticals. A generic medicine is a medication designed to be identical as branded drugs marketed by private companies in dosage form, strength, safety, route of administration, performance characteristics, quality, and intended use. Generic drugs work in the same way as branded drugs in terms of clinical benefits. Generic drugs are manufactured after the expiration of the exclusive rights or patent of the branded drugs. For example, some of the generic drugs in the generic pharmaceuticals market include metformin, metoprolol, acarbose, acebutolol, aztreonam and many more. The main types of generic pharmaceuticals are biosimilar; simple generic and super generic. A biosimilar is a biological product that is very similar to a reference biologic and has no clinically significant differences in terms of safety, purity, or potency. The drugs are delivered through oral, injectables, dermal/topical and inhaler that are used for various therapies such as CNS, cardiovascular, dermatology, genitourinary/hormonal, respiratory, rheumatology, diabetes and oncology. The various distribution channel involved are hospital pharmacies, retail pharmacies and online pharmacies. North America was the largest region in the generic pharmaceuticals market in 2021. Middle East is expected to be the largest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The rising incidence of chronic diseases is one of the major drivers of the generic pharmaceuticals market. As more individuals are diagnosed with chronic diseases, they look for more medicines for the treatment. Branded drugs come at a premium price, while generic drugs are available at a lower cost having the same chemical composition of branded drugs. The low cost and same chemical composition and strength of generic drugs make a patient buy generic drugs instead of branded drugs. If it is a chronic disease, the treatment goes for a longer period of time and hence, the sales of generic drugs also increase. For instance, according to the WHO (World Health Organization), over the next 10 years, the deaths due to chronic disease is projected to increase by 17%. Also, in 2020, almost 3-quarters of all deaths in the world is due to chronic diseases. The lack of awareness about generic drugs is one of the restraints on the generic pharmaceuticals market. The high marketing and advertisement of branded drugs overshadow the availability of generic drugs which are substitute for expensive branded drugs. Thus, consumers opt branded drugs despite the fact that the generic drugs carry the same chemical formulation as their counter branded drugs. According to an article published on CVS HEALTH, many doctors and pharmacists preferred to offer branded drugs to their patients over generic drugs. This prevents the patients to go for generic drugs as they develop a preconceived notion of generic drugs not being at par with branded drugs. For example, according to a research conducted by Sahana K Hebbar, on International Journal of Basic & Clinical Pharmacology, out of 100 patients and 50 non-medical staff, 95% of the patients and 60% of the non-medical staff didn't know about generic drugs. Thus, lack of awareness about the availability of generic drugs hamper the generic pharmaceuticals market. 3D printing technology has the ability to transform the manufacturing of drugs in the generic pharmaceuticals market. 3D printed pharmaceuticals help in improve R&D productivity and deliver new benefits to patients. 3D printing allows the manufacturer to produce drugs with customized size, shape, and texture which is not possible in traditional manufacturing of generic drugs. 3D printing can help the manufacturer to make generic drugs that have different release dates, appearances and taste. For example, GlaxoSmithKline (GSK) completed a study where ultraviolet (UV) and 3D printing were used to manufacture tablets to treat Parkinson's disease. Martin Wallace, director of GSK Technology, said that GSK is investing in 3D printing advantages to manufacture pills and tablets. Also, Aprecia pharmaceutical company launched 'ZipDose' technology which manufactures 3D printed drugs. The drug manufacturers must comply with the CGMP (Current Good Manufacturing Practice) regulations that come under the US Food and Drug Administration (FDA) which includes generic pharmaceuticals. The CGMP regulations require manufacturers to maintain a minimum quality standard for the methods, controls, and facilities used in manufacturing, packaging, and processing of drug product. The part- 99 of chapter 1 under title 21-Food And Drugs of CFR (Code of Federal Regulations) contains subparts from A to H. The whole part-99 describes the guidelines that need to be followed by drug manufacturers regarding the dissemination of information on human drugs, including biologics, and devices. The guidelines concern with the safety, effectiveness, or benefit of use that is not included in the approved labelling for a drug or device approved by the Food and Drug Administration for marketing. The guidelines regulate the information regarding the drugs that should be delivered to the health care practitioner, pharmacy benefit manager, health insurance issuer, group health plan, or federal or state government agency. Generic Pharmaceuticals Market Competitive Landscape And Company Profiles Teva Pharmaceuticals Mylan NV Sandoz International GmbH Hospira (Pfizer inc.) Sun Pharmaceutical Lupin Limited Endo International plc. Dr Reddy's Laboratories Apotex Holdings Fresenius Kabi Ag Aurbindo Pharma Aspen Pharmacare Sanofi Cipla Hikma Pharmaceuticals Stada Arzneimittel Krka Group Nichi-Iko Pharmaceutical Valeant Zydus Cadila Merck & Co. Mitsubishi Tanabe Pharma Momenta Pharmaceuticals Nexus Pharmaceuticals Novo Nordisk Ranbaxy Laboratories Ltd. Sawai Pharmaceuticals Novartis AG Pfizer Johnson & Johnson Services Key Topics Covered: 1. Executive Summary 2. Generic Pharmaceuticals Market Characteristics 3. Generic Pharmaceuticals Market Trends And Strategies 4. Impact Of COVID-19 On Generic Pharmaceuticals 5. Generic Pharmaceuticals Market Size And Growth 5.1. Global Generic Pharmaceuticals Historic Market, 2016-2021, $ Billion 5.1.1. Drivers Of The Market 5.1.2. Restraints On The Market 5.2. Global Generic Pharmaceuticals Forecast Market, 2021-2026F, 2031F, $ Billion 5.2.1. Drivers Of The Market 5.2.2. Restraints On the Market 6. Generic Pharmaceuticals Market Segmentation 6.1. Global Generic Pharmaceuticals Market, Segmentation By Therapy, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion CNS Cardiovascular Dermatology Genitourinary/Hormonal Respiratory Rheumatology Diabetes Oncology 6.2. Global Generic Pharmaceuticals Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion Hospital Pharmacies Retail Pharmacies Online Pharmacies 6.3. Global Generic Pharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion Biosimilar Simple Generic Super Generic 6.4. Global Generic Pharmaceuticals Market, Segmentation By Drug Delivery, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion Oral Injectables Dermal/Topical Inhaler 7. Generic Pharmaceuticals Market Regional And Country Analysis 7.1. Global Generic Pharmaceuticals Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion 7.2. Global Generic Pharmaceuticals Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

FRAMINGHAM, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced it has closed on the previously announced private placement of 43,125,004 shares of its common stock and warrants to purchase up to an aggregate of 32,343,753 shares of common stock, at a combined purchase price of $0.16 per share of common stock and associated warrant in a private placement. The gross proceeds to Arch from the private placement before deducting underwriting commissions and other offering expenses payable by Arch is $6.9 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The warrants have an exercise price of $0.17 per share, are exercisable immediately and have a term of 5.5 years. The Company currently intends to use the net proceeds from the offering to expand and accelerate commercialization efforts, manufacture/produce additional finished inventory, and advance pipeline programs. Terrence W. Norchi, MD, President and Chief Executive Officer of Arch, stated, “This is a pivotal year for Arch. We appreciate the enthusiastic support of both our long-standing current investors and our new institutional investors. We look forward to advancing our commercially available Dermal Sciences products as well as our pipeline stage Biosurgery products, which we believe hold tremendous potential.” The Company has recently announced commencement of commercial sales of AC5® Advanced Wound System, its first product in the United States. The Company also recently executed an agreement with Buffalo Supply, Inc. to be the distributor of products sold to United States government channels. Dr. Norchi added, “With inventory in possession and a distributor engaged to support sales to government facilities with support from independent sales representatives, we believe we are better positioned to commercialize AC5 Advanced Wound System to meet the underserved wound care markets.” Dr. Norchi further noted, “The impact of the COVID-19 pandemic in 2020 on the capacity of hospitals and surgeons to intake new technology and new products was remarkable, as many institutions were focused on new challenges. While we envision some headwinds to continue in 2021 for us and many in the medical industry, we believe that AC5 Advanced Wound System is well positioned to enable surgeons to address their patient’s challenging wounds. These wounds are all too often being treated electively when instead they should be addressed emergently in order to hopefully accelerate wound healing to better preserve limbs and possibly save lives.” Dr. Norchi concluded, “We believe that 2021 will be an exciting year for Arch while we continue to make progress towards maximizing the value of the intellectual property portfolios both developed at Arch and licensed exclusively worldwide from Massachusetts Institute of Technology and Versitech Limited.” The securities described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”) and Regulation D promulgated thereunder and, in a transaction, not involving a public offering and have not been registered under the Act or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. About Arch Therapeutics, Inc. Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5® Advanced Wound System and AC5® Topical Hemostat as medical devices in the United States and Europe, respectively. Arch's development stage product candidates include AC5-G™, AC5-V® and AC5® Surgical Hemostat, among others.1,2 Notice Regarding Forward-Looking Statements This news release contains “forward-looking statements” as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the intended use of net proceeds from the private placement, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to obtain required regulatory approvals, our ability to produce commercial quantities of our products within projected timeframes, our ability to develop and commercialize products based on our technology platform, and market conditions, and our ability to establish additional commercialization partnerships and build a critical mass of field sales representatives. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at . 1 AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use. 2 AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries. Contact: ARTH Investor Relations Toll Free: +1-855-340-ARTH (2784) (US and Canada) Email: investors@archtherapeutics.com Website: or Richard Davis Chief Financial Officer Arch Therapeutics, Inc. Phone: 617-431-2308 Email: rdavis@archtherapeutics.com Website: